{"id":"W2007084442","doi":"10.2147/dddt.s14071","title":"A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients","year":2010,"lang":"en","type":"article","venue":"Drug Design Development and Therapy","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Viventia Bio (Canada)","funders":"","keywords":"Medicine; Tolerability; Refractory (planetary science); Adverse effect; Bladder cancer; Urology; Toxicity; Pharmacokinetics; Internal medicine; Maximum tolerated dose; Clinical endpoint; Gastroenterology; Surgery; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002205308,0.00024685,0.000441879,0.00009967996,0.0001061341,0.00001602817,0.00007864922,0.0000608539,0.00004168862],"category_scores_gemma":[0.00001398161,0.0001510861,0.00004213485,0.00009124906,0.00008170124,0.00007458591,0.00001112937,0.00008734746,2.434367e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000462694,"about_ca_system_score_gemma":0.0002929751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002027071,"about_ca_topic_score_gemma":0.0002661431,"domain_scores_codex":[0.9987538,0.00007042191,0.0004609244,0.0003002549,0.0001995693,0.0002150594],"domain_scores_gemma":[0.9991832,0.0002327502,0.0001749596,0.0001925734,0.000123588,0.00009288238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.008878768,0.0217284,0.03727768,0.00006254874,0.001197869,0.0000116529,0.09580312,0.00000309097,0.07179661,0.000003977026,0.00001860756,0.7632177],"study_design_scores_gemma":[0.1058747,0.02634784,0.397004,0.000160685,0.0003113608,0.000004064525,0.00627158,0.000215134,0.4614384,0.00005083389,0.001828425,0.0004929246],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951558,0.001367514,0.00006455676,0.00006684577,0.0001258479,0.003173894,0.00002293323,0.000009776753,0.0000127914],"genre_scores_gemma":[0.9962613,0.001369052,0.001476938,0.00006685591,0.00004612296,0.0006826164,0.00002110407,0.00002839111,0.00004761114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7627248,"threshold_uncertainty_score":0.6161114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03116886744117042,"score_gpt":0.3167600006688397,"score_spread":0.2855911332276693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}